Skip to main content
main-content

Expert opinion

Neuer Inhalt Free registration

Gain full access to the latest clinical content available from Springer Nature


Concise and thought-provoking commentary, opinion, and analysis from leading oncology experts.

02-02-2018 | Chronic myeloid leukemia | Editorial | Article

Discontinuing tyrosine kinase inhibitors in chronic myeloid leukemia

Tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) can result in prolonged and deep responses in many patients. In such cases, can TKIs be safely discontinued to avoid adverse side effects and costs? Here, Etab Atallah discusses the current issues surrounding TKI discontinuation in CML.

Author:
Ehab Atallah MD

22-01-2018 | Non-small cell lung cancer | Editorial | Collection

Pembrolizumab-chemotherapy combination in non-small cell lung cancer

Two editorials provide differing opinions on using pembrolizumab with pemetrexed and platinum chemotherapy for non-small cell lung cancer. In the first article, Stephen Liu argues for embracing this new treatment option, while in the second, Sally Lau and Natasha Leighl argue for a little more caution.

08-01-2018 | Breast cancer | Editorial | Article

New paradigm: Testing elimination of breast cancer surgery after neoadjuvant systemic therapy

Neoadjuvant chemotherapy can be so effective at shrinking breast tumors in some patients that it has raised the possibility of avoiding surgery altogether. Here, Henry Kuerer discusses exciting recent advances in this area.

Author:
Henry Kuerer MD, PhD, FACS

04-01-2018 | Small cell lung cancer | Editorial | Article

Progress in small cell lung cancer: an update from the 2017 IASLC World Conference on Lung Cancer, Yokohama, Japan

Advisory Board member Fiona Blackhall discusses the major new results in small cell lung cancer presented at the 2017 IASLC World Conference on Lung Cancer, Yokohama, Japan.

Author:
Fiona Blackhall PhD, FRCP

19-12-2017 | Ovarian cancer | Editorial | Article

Fertility-sparing surgery in high-risk epithelial ovarian cancer: from the patients wishes to the precautionary principle

Fertility-sparing surgery is an important option for young women with ovarian cancer but there are questions surrounding its safety in all cases. Here, Philippe Morice and Sébastien Gouy discuss the problems faced in high-risk cases.

Authors:
Philippe Morice MD, PhD, Sébastien Gouy MD, PhD

26-07-2017 | Non-small cell lung cancer | Editorial | Article

Changing landscape of treatment for ALK-positive non-small cell lung cancer

Tremendous advances have been made in the treatment of ALK-positive lung cancers. Here, Advisory Board member Fiona Blackhall summarizes recent developments in the field and discusses current management hurdles, including development of resistance to ALK inhibitors.

Author:
Fiona Blackhall PhD, FRCP

28-04-2017 | Genitourinary cancers | Editorial | Article

Highlights from the 2017 Genitourinary Cancer Symposium (ASCO-GU), Orlando, Florida, USA

Advisory Board member Prof Axel Merseburger discusses the key outcomes from the 2017 ASCO-GU Congress in Orlando, Florida.

Author:
Axel S Merseburger MD

14-03-2017 | Leukemia | Editorial | Article

FMS-like tyrosine kinase 3 (FLT3)-inhibition in FLT3 mutated acute myeloid leukemia: A promising approach

Advisory Board Member Xavier Thomas discusses the potential of FLT3 inhibitors for the treatment of acute myeloid leukemia.

Author:
Xavier Thomas MD

26-01-2017 | Hematologic cancers | Editorial | Article

Immunotherapy comes of age in blood cancers

Advisory Board member Jasmine Zain discusses the development of various immunotherapy approaches and their potential clinical benefits for patients with blood cancers.

Author:
Jasmine Zain MD
image credits